Pliant Therapeutics, Inc. (PLRX)
$0.99-2.94%Close
SELLBEAR · day 2
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $61M
- Beta
- 1.28
- P/E (TTM)
- -0.69
- Short % float
- 7.41%
- Days to cover
- 11.4
- SI change
- +15.0%
- 1W
- -3.88%
- 1M
- -15.38%
- vs SPY 1W
- -4.31%
- vs SPY 1M
- -17.45%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 10
- VALUE
- 12
- GROWTH
- 45
- GARP
- 6
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-31.9%
REV YoY-
ROE-53.2%
EPS YoY-
ROA-48.6%
GROSS0
OP0
NET0
[VALUATION]
P/E TTM-0.69
P/E FWD-
SECTOR PE20.34
INDUSTRY PE13.84
P/B0.43
P/FCF-
EV/EBITDA-0.77
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E19.56
ALTMAN Z-
CURR RATIO9.90
ND/EBITDA-
BETA1.28
Company news
FAQ
- What is LOPJLB’s current signal on PLRX?
- LOPJLB’s latest quantitative signal on Pliant Therapeutics, Inc. (PLRX) is SELL in a BEAR regime. Signals are updated daily.
- What market regime is PLRX in?
- Pliant Therapeutics, Inc. (PLRX) is currently classified in the BEAR HMM market regime on LOPJLB.
- What does Pliant Therapeutics, Inc. (PLRX) do?
- Pliant Therapeutics, Inc. is a biopharmaceutical company in the clinical development stage, dedicated to discovering, advancing, and bringing to market innovative therapies for fibrotic and related diseases across the United States. Its flagship investigational product, PLN-74809, is an orally administered, small-molecule, dual-selective inhibitor targeting both avÃ6 and avÃ1 integrins, which…